

## **Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results**

**Leverkusen, Germany, November 6, 2019** – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2019 on November 19, 2019.

Conference calls for shareholders and interested investors will be held on November 19, 2019 at the following times:

In German, at 10:00 am CET (4:00 am ET)  
Dial-in number Germany: +49 69201744220  
Conference code: 95804724#

In English, at 2:00 pm CET (8:00 am ET)  
Dial-in number USA: +1 8774230830  
Dial-in number UK: +44 2030092470  
Conference code: 49165242#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

**-End-**

**For enquiries, please contact:**

<b>Biofrontera AG</b>	+49 (0) 214 87 63 2 0
Thomas Schaffer, Chief Financial Officer	ir@biofrontera.com
<b>IR UK: Seton Services</b>	
Toni Vallen	+44 (0) 207 229 0805
<b>IR and PR US: The Ruth Group</b>	
IR: Tram Bui	+1 646-536-7035
PR: Kirsten Thomas	+1 508-280-6592

**About Biofrontera:**

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription

medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. [www.biofrontera.com](http://www.biofrontera.com).

#### **Biofrontera AG**

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany  
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90  
[info@biofrontera.com](mailto:info@biofrontera.com) | [www.biofrontera.com](http://www.biofrontera.com)

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)  
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)  
Christoph Dünwald (CCO) | Thomas Schaffer (CFO)  
**Commercial register:** Handelsregister Köln | **Register number:** HR B 49717 (AG)  
**VAT-identification number according to § 27 a UStG VAT act:** DE 812374102